The German Cardiosurgery Atrial Fibrillation Registry: 1-Year Follow-up Outcomes

Abstract

Objectives This study of German Cardiosurgery Atrial Fibrillation (CASE-AF) registry aims to describe the 1-year outcomes of patients undergoing ablative procedures for atrial fibrillation (AF) in a cardiosurgical setting.

Methods Between January 2017 and April 2020, 17 German cardiosurgical units enrolled 1,000 consecutive patients undergoing concomitant or stand-alone ablation for AF. In-hospital and 1-year follow-up data were collected on web-based electronic case report forms. The protocol mandated telephone-based follow-up contact after 1 year.

Results At 1-year follow-up (median, 14.5 months [12.6–18.2 months]), significant improvement (p < 0.0001) in baseline modified European Heart Rhythm Association Class I was reported in both concomitant and stand-alone patients. Follow-up examinations were completed in 97.9% of cases, and a sinus rhythm was reported in 60.2 and 63.6% of stand-alone and concomitant patients, respectively. Statistically significant factors determining late recurrence were female gender (p = 0.013), preoperative persistent AF (p < 0.0001), and presence of cardiac implantable electronic device (p = 0.011). All-cause mortality at 1 year was 1% (n = 1) in stand-alone patients and 6.7% (n = 58) in concomitant patients.

Conclusion Surgical ablation of AF is safe and provides satisfactory results at short-term follow-up, with significant improvement in patient symptoms. Adequate cardiac rhythm monitoring should be prioritized for higher quality data acquisition.

Keywords

arrhythmia therapy - minimally invasive surgery - heart valve surgery

Note

ClinicalTrials.gov Identifier: NCT03091452. https://clinicaltrials.gov/ct2/show/NCT03091452.

Publikationsverlauf

Eingereicht: 13. März 2022

Angenommen: 12. Mai 2022

Artikel online veröffentlicht:
27. Juli 2022

• References

• 1 Cox JL, Schuessler RB, Boineau JP. The development of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 2000; 12 (01) 2-14
• 2 Wehbe M, Albert M, Lewalter T. et al; CASE-AF Investigators. The German CArdioSurgEry Atrial Fibrillation registry: in-hospital outcomes. Thorac Cardiovasc Surg 2021; (e-pub ahead of print).
• 3 Kirchhof P, Benussi S, Kotecha D. et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
• 4 Wynn GJ, Todd DM, Webber M. et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace 2014; 16 (07) 965-972
• 5 Calkins H, Hindricks G, Cappato R. et al; Document Reviewers. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2018; 20 (01) e1-e160
• 6 Erdogan A, Carlsson J, Neumann T. et al. Quality-of-life in patients with paroxysmal atrial fibrillation after catheter ablation: results of long-term follow-up. Pacing Clin Electrophysiol 2003; 26 (03) 678-684
• 7 Grady KL, Lee R, Subačius H. et al. Improvements in health-related quality of life before and after isolated cardiac operations. Ann Thorac Surg 2011; 91 (03) 777-783
• 8 Kasirajan V, Spradlin EA, Mormando TE. et al. Minimally invasive surgery using bipolar radiofrequency energy is effective treatment for refractory atrial fibrillation. Ann Thorac Surg 2012; 93 (05) 1456-1461
• 9 Walfridsson H, Walfridsson U, Nielsen JC. et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial. Europace 2015; 17 (02) 215-221
• 10 Driessen AHG, Berger WR, Bierhuizen MFA. et al. Quality of life improves after thoracoscopic surgical ablation of advanced atrial fibrillation: results of the Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic Surgery (AFACT) study. J Thorac Cardiovasc Surg 2018; 155 (03) 972-980
• 11 Raissouni K, Petrosyan A, Malapert G, Jazayeri S, Morgant MC, Bouchot O. Concomitant cardiac surgery and radiofrequency ablation of atrial fibrillation: a retrospective single center study. J Cardiothorac Vasc Anesth 2020; 34 (02) 401-408
• 12 Blomström-Lundqvist C, Johansson B, Berglin E. et al. A randomized double-blind study of epicardial left atrial cryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery: the SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). Eur Heart J 2007; 28 (23) 2902-2908
• 13 Abreu Filho CAC, Lisboa LAF, Dallan LAO. et al. Effectiveness of the maze procedure using cooled-tip radiofrequency ablation in patients with permanent atrial fibrillation and rheumatic mitral valve disease. Circulation 2005; 112 (9, Suppl): I20-I25
• 14 Verma A, Champagne J, Sapp J. et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med 2013; 173 (02) 149-156
• 15 Arbelo E, Brugada J, Blomström-Lundqvist C. et al; on the behalf of the ESC-EHRA Atrial Fibrillation Ablation Long-term Registry Investigators. Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. Eur Heart J 2017; 38 (17) 1303-1316
• 16 Haldar S, Khan HR, Boyalla V. et al. Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial. Eur Heart J 2020; 41 (47) 4471-4480
• 17 Cox JL. The surgical treatment of atrial fibrillation. IV. Surgical technique. J Thorac Cardiovasc Surg 1991; 101 (04) 584-592
• 18 Cox JL, Ad N, Palazzo T. et al. Current status of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 2000; 12 (01) 15-19
• 19 Pison L, La Meir M, van Opstal J, Blaauw Y, Maessen J, Crijns HJ. Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll Cardiol 2012; 60 (01) 54-61
• 20 Maesen B, Pison L, Vroomen M. et al. Three-year follow-up of hybrid ablation for atrial fibrillation. Eur J Cardiothorac Surg 2018; 53 (Suppl. 01) i26-i32
• 21 Gaynor SL, Schuessler RB, Bailey MS. et al. Surgical treatment of atrial fibrillation: predictors of late recurrence. J Thorac Cardiovasc Surg 2005; 129 (01) 104-111
• 22 Pecha S, Schäfer T, Subbotina I, Ahmadzade T, Reichenspurner H, Wagner FM. Rhythm outcome predictors after concomitant surgical ablation for atrial fibrillation: a 9-year, single-center experience. J Thorac Cardiovasc Surg 2014; 148 (02) 428-433
• 23 Gillinov AM, Bhavani S, Blackstone EH. et al. Surgery for permanent atrial fibrillation: impact of patient factors and lesion set. Ann Thorac Surg 2006; 82 (02) 502-513 , discussion 513–514
• 24 Sultan A, Lüker J, Andresen D. et al. Predictors of atrial fibrillation recurrence after catheter ablation: data from the German Ablation registry. Sci Rep 2017; 7 (01) 16678
• 25 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
• 26 Huffman MD, Karmali KN, Berendsen MA. et al. Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. Cochrane Database Syst Rev 2016; (08) CD011814
• 27 Wehbe MS, Doll N, Merk DR. Fatal complications associated with surgical left atrial appendage exclusion. J Thorac Cardiovasc Surg 2018; 156 (06) e207-e208
• 28 Hanke T, Charitos EI, Stierle U. et al. Twenty-four-hour holter monitor follow-up does not provide accurate heart rhythm status after surgical atrial fibrillation ablation therapy: up to 12 months experience with a novel permanently implantable heart rhythm monitor device. Circulation 2009; 120 (11, Suppl): S177-S184